Prognostic implications were further elucidated using the Kaplan–Meier Plotter, revealing a significant linkage between heightened MAP7 expression and diminished progression-free survival (PFS) and overall survival (OS) among ovarian cancer patients (Fig. 1D and E), thus underscoring the potential of MAP7 upregulation as an indicator of poor clinical outcome. Here, MAP7 is linked to ovarian carcinoma.